Granted Patent B2

US 7,879,328 · App. 11/054,515 · Granted Feb 1, 2011

Assignee: Human Genome Sciences, Inc.

Abstract

Claims (147)

1. A method of antagonizing B Lymphocyte Stimulator activity in an animal having systemic lupus erythematosus or rheumatoid arthritis comprising administering to the animal an antibody comprising a first amino acid sequence that is at least 85% identical to amino acid residues 1-123 of SEQ ID NO:327 and a second amino acid sequence that is at least 85% identical to amino acid residues 141-249 of SEQ ID NO:327, and wherein the antibody binds B Lymphocyte Stimulator selected from the group consisting of:

(a) amino acid residues 1-285 of SEQ ID NO: 3228;

(b) amino acid residues 134-285 of SEQ ID NO: 3228; and

(c) a trimer comprising amino acid residues 134-285 of SEQ ID NO:3228.

2. A method of antagonizing B Lymphocyte Stimulator activity in a human patient having rheumatoid arthritis comprising administering to the human patient an antibody comprising a first amino acid sequence that is at least 85% identical to amino acid residues 1-123 of SEQ ID NO:327 and a second amino acid sequence that is at least 85% identical to amino acid residues 141-249 of SEQ ID NO:327, wherein the antibody binds B Lymphocyte Stimulator selected from the group consisting of:

(a) amino acid residues 1-285 of SEQ ID NO: 3228;

(b) amino acid residues 134-285 of SEQ ID NO: 3228; and

(c) a trimer comprising amino acid residues 134-285 of SEQ ID NO:3228.

3. The method of claim 2 further comprising administering one or more agents employed for treating rheumatoid arthritis selected from the group consisting of:

(a) a non-steroidal anti-inflammatory drug;

(b) an anti-malarial agent;

(c) a steroid;

(d) a cytotoxic agent;

(e) an immunosuppressive agent; and

(f) an anti-angiogenic factor.

4. The method of claim 2 further comprising administering one or more agents employed for treating rheumatoid arthritis selected from the group consisting of:

(a) a TNF antagonist;

(b) an anti-CD20 antibody;

(c) an interleukin-1 antagonist;

(d) CTLA4-Ig;

(e) methotrexate;

(f) leflunomide;

(g) sulfasalazine;

(h) auranofin;

(i) gold;

(j) azathioprine;

(k) penicillamine;

(l) cyclophosphamide; and

(m) cyclosporine.

5. A method of antagonizing B Lymphocyte Stimulator activity in a human patient having systemic lupus erythematosus comprising administering to the human patient an antibody comprising a first amino acid sequence that is at least 85% identical to amino acid residues 1-123 of SEQ ID NO:327 and a second amino acid sequence that is at least 85% identical to amino acid residues 141-249 of SEQ ID NO:327, wherein the antibody binds B Lymphocyte Stimulator selected from the group consisting of:

(a) amino acid residues 1-285 of SEQ ID NO: 3228;

(b) amino acid residues 134-285 of SEQ ID NO: 3228; and

(c) a trimer comprising amino acid residues 134-285 of SEQ ID NO:3228.

6. The method of claim 5 further comprising administering one or more agents employed for treating systemic lupus erythematosus selected from the group consisting of:

(a) a non-steroidal anti-inflammatory drug;

(b) an anti-malarial agent;

(c) a steroid;

(d) a cytotoxic agent;

(e) an immunosuppressive agent; and

(f) an anti-angiogenic factor.

7. The method of claim 5 further comprising administering one or more agents employed for treating systemic lupus erythematosus selected from the group consisting of:

(a) a TNF antagonist;

(b) an anti-CD20 antibody;

(c) an interleukin-1 antagonist;

(d) CTLA4-Ig;

(e) methotrexate;

(f) leflunomide;

(g) sulfasalazine;

(h) auranofin;

(i) gold;

(j) azathioprine;

(k) penicillamine;

(l) cyclophosphamide; and

(m) cyclosporine.

8. The method of claim 1 , wherein the antibody is administered by a route selected from the group consisting of intravenous and subcutaneous.

9. The method of claim 2 , wherein the antibody is administered by a route selected from the group consisting of intravenous and subcutaneous.

10. The method of claim 5 , wherein the antibody is administered by a route selected from the group consisting of intravenous and subcutaneous.

11. The method of claim 3 , wherein the agent employed for treating rheumatoid arthritis is a non-steroidal anti-inflammatory drug.

12. The method of claim 3 , wherein the agent employed for treating rheumatoid arthritis is an anti-malarial agent.

13. The method of claim 3 , wherein the agent employed for treating rheumatoid arthritis is a steroid.

14. The method of claim 3 , wherein the agent employed for treating rheumatoid arthritis is a cytotoxic agent.

15. The method of claim 3 , wherein the agent employed for treating rheumatoid arthritis is an immunosuppressive agent.

16. The method of claim 3 , wherein the agent employed for treating rheumatoid arthritis is an anti-angiogenic factor.

17. The method of claim 6 , wherein the agent employed for treating systemic lupus erythematosus is a non-steroidal anti-inflammatory drug.

18. The method of claim 6 , wherein the agent employed for treating systemic lupus erythematosus is an anti-malarial agent.

19. The method of claim 6 , wherein the agent employed for treating systemic lupus erythematosus is a steroid.

20. The method of claim 6 , wherein the agent employed for treating systemic lupus erythematosus is a cytotoxic agent.

21. The method of claim 6 , wherein the agent employed for treating systemic lupus erythematosus is an immunosuppressive agent.

22. The method of claim 6 , wherein the agent employed for treating systemic lupus erythematosus is an anti-angiogenic factor.

23. The method of claim 7 , wherein the agent employed for treating systemic lupus erythematosus is a TNF antagonist.

24. The method of claim 7 , wherein the agent employed for treating systemic lupus erythematosus is an anti-CD20 antibody.

25. The method of claim 7 , wherein the agent employed for treating systemic lupus erythematosus is an interleukin-1 antagonist.

26. The method of claim 7 , wherein the agent employed for treating systemic lupus erythematosus is CTLA4-Ig.

27. The method of claim 7 , wherein the agent employed for treating systemic lupus erythematosus is methotrexate.

28. The method of claim 7 , wherein the agent employed for treating systemic lupus erythematosus is leflunomide.

29. The method of claim 7 , wherein the agent employed for treating systemic lupus erythematosus is cyclosporine.

30. The method of claim 1 , wherein the first amino acid sequence is at least 95% identical to amino acid residues 1-123 of SEQ ID NO:327 and the second amino acid sequence is at least 95% identical to amino acid residues 141-249 of SEQ ID NO:327.

31. The method of claim 2 , wherein the first amino acid sequence is at least 95% identical to amino acid residues 1-123 of SEQ ID NO:327 and the second amino acid sequence is at least 95% identical to amino acid residues 141-249 of SEQ ID NO:327.

32. The method of claim 5 , wherein the first amino acid sequence is at least 95% identical to amino acid residues 1-123 of SEQ ID NO:327 and the second amino acid sequence is at least 95% identical to amino acid residues 141-249 of SEQ ID NO:327.

33. The method of claim 1 , wherein the first amino acid sequence comprises amino acid residues 1-123 of SEQ ID NO:327 and the second amino acid sequence comprises amino acid residues 141-249 of SEQ ID NO:327.

34. The method of claim 2 , wherein the first amino acid sequence is comprises amino acid residues 1-123 of SEQ ID NO:327 and the second amino acid sequence comprises amino acid residues 141-249 of SEQ ID NO:327.

35. The method of claim 5 , wherein the first amino acid sequence comprises amino acid residues 1-123 of SEQ ID NO:327 and the second amino acid sequence comprises amino acid residues 141-249 of SEQ ID NO:327.

36. The method of claim 17 , wherein the first amino acid sequence comprises amino acid residues 1-123 of SEQ ID NO:327 and the second amino acid sequence comprises amino acid residues 141-249 of SEQ ID NO:327.

37. The method of claim 18 , wherein the first amino acid sequence comprises amino acid residues 1-123 of SEQ ID NO:327 and the second amino acid sequence comprises amino acid residues 141-249 of SEQ ID NO:327.

38. The method of claim 19 , wherein the first amino acid sequence comprises amino acid residues 1-123 of SEQ ID NO:327 and the second amino acid sequence comprises amino acid residues 141-249 of SEQ ID NO:327.

39. The method of claim 20 , wherein the first amino acid sequence comprises amino acid residues 1-123 of SEQ ID NO:327 and the second amino acid sequence comprises amino acid residues 141-249 of SEQ ID NO:327.

40. The method of claim 21 , wherein the first amino acid sequence comprises amino acid residues 1-123 of SEQ ID NO:327 and the second amino acid sequence comprises amino acid residues 141-249 of SEQ ID NO:327.

41. The method of claim 22 , wherein the first amino acid sequence comprises amino acid residues 1-123 of SEQ ID NO:327 and the second amino acid sequence comprises amino acid residues 141-249 of SEQ ID NO:327.

42. The method of claim 23 , wherein the first amino acid sequence comprises amino acid residues 1-123 of SEQ ID NO:327 and the second amino acid sequence comprises amino acid residues 141-249 of SEQ ID NO:327.

43. The method of claim 24 , wherein the first amino acid sequence comprises amino acid residues 1-123 of SEQ ID NO:327 and the second amino acid sequence comprises amino acid residues 141-249 of SEQ ID NO:327.

44. The method of claim 25 , wherein the first amino acid sequence comprises amino acid residues 1-123 of SEQ ID NO:327 and the second amino acid sequence comprises amino acid residues 141-249 of SEQ ID NO:327.

45. The method of claim 26 , wherein the first amino acid sequence comprises amino acid residues 1-123 of SEQ ID NO:327 and the second amino acid sequence comprises amino acid residues 141-249 of SEQ ID NO:327.

46. The method of claim 27 , wherein the first amino acid sequence comprises amino acid residues 1-123 of SEQ ID NO:327 and the second amino acid sequence comprises amino acid residues 141-249 of SEQ ID NO:327.

47. The method of claim 28 , wherein the first amino acid sequence comprises amino acid residues 1-123 of SEQ ID NO:327 and the second amino acid sequence comprises amino acid residues 141-249 of SEQ ID NO:327.

48. The method of claim 29 , wherein the first amino acid sequence comprises amino acid residues 1-123 of SEQ ID NO:327 and the second amino acid sequence comprises amino acid residues 141-249 of SEQ ID NO:327.

49. A method of antagonizing B Lymphocyte Stimulator activity in a patient having systemic lupus erythematosus or rheumatoid arthritis comprising administering an antibody to the patient,

wherein the antibody comprises amino acid residues 26-35, 50-66, 99-112, 163-173, 189-195, and 228-238 of SEQ ID NO: 327, and

wherein the antibody binds B Lymphocyte Stimulator selected from the group consisting of:

(a) amino acid residues 1-285 of SEQ ID NO: 3228;

(b) amino acid residues 134-285 of SEQ ID NO: 3228; and

(c) a trimer comprising amino acid residues 134-285 of SEQ ID NO: 3228.

50. The method of claim 49 , wherein the patient has systemic lupus erythematosus.

51. The method of claim 50 , wherein the antibody is administered by a route selected from the group consisting of intravenous and subcutaneous.

52. The method of claim 50 further comprising administering one or more agents employed for treating systemic lupus erythematosus selected from the group consisting of:

a. a non-steroidal anti-inflammatory drug;

b. an anti-malarial agent;

c. a steroid;

d. a cytotoxic agent;

e. an immunosuppressive agent; and

f. an anti-angiogenic factor.

53. The method of claim 50 further comprising administering one or more agents employed for treating systemic lupus erythematosus selected from the group consisting of:

a. a TNF antagonist;

b. an anti-CD20 antibody;

c. an interleukin-1 antagonist;

d. CTLA4-Ig;

e. methotrexate;

f. leflunomide;

g. sulfasalazine;

h. auranofin;

i. gold;

j. azathioprine;

k. penicillamine;

l. cyclophosphamide; and

m. cyclosporine.

54. The method of claim 49 , wherein the patient has rheumatoid arthritis.

55. The method of claim 54 , wherein the antibody is administered by a route selected from the group consisting of intravenous and subcutaneous.

56. The method of claim 54 further comprising administering one or more agents employed for treating rheumatoid arthritis selected from the group consisting of:

a. a non-steroidal anti-inflammatory drug;

b. an anti-malarial agent;

c. a steroid;

d. a cytotoxic agent;

e. an immunosuppressive agent; and

f. an anti-angiogenic factor.

57. The method of claim 54 further comprising administering one or more agents employed for treating rheumatoid arthritis selected from the group consisting of:

a. a TNF antagonist;

b. an anti-CD20 antibody;

c. an interleukin-1 antagonist;

d. CTLA4-Ig;

e. methotrexate;

f. leflunomide;

g. sulfasalazine;

h. auranofin;

i. gold;

j. azathioprine;

k. penicillamine;

l. cyclophosphamide; and

m. cyclosporine.

Assignments (3)

Continuity (12)